Lack of positive effect of intravitreal bevacizumab in central serous chorioretinopathy: Meta-analysis and review

Eye (Basingstoke)

Volumn 27, Issue 12, 2013, Pages 1339-1346

  Chung, Y R ^a   Seo, E J ^a   Lew, H M ^a   Lee, K H ^a  

^a Ajou University School of Medicine   (South Korea)

Author keywords

Central serous chorioretinopathy; Intravitreal bevacizumab injection; Meta analysis

Indexed keywords

BEVACIZUMAB;

ARTICLE; CENTRAL MACULAR THICKNESS; CENTRAL SEROUS RETINOPATHY; CONJUNCTIVAL HEMORRHAGE; DRUG EFFECT; HUMAN; INJECTION SITE BLEEDING; META ANALYSIS; OUTCOME ASSESSMENT; SYSTEMATIC REVIEW; TREATMENT DURATION; TREATMENT OUTCOME; VISUAL ACUITY;

ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL, HUMANIZED; CENTRAL SEROUS CHORIORETINOPATHY; HUMANS; INTRAVITREAL INJECTIONS; TREATMENT OUTCOME; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VISUAL ACUITY;

EID: 84890493005     PISSN: 0950222X     EISSN: 14765454     Source Type: Journal    
DOI: 10.1038/eye.2013.236     Document Type: Article

References (50)

1. Seong HK, Bae JH, Kim ES, Han JR, Nam WH, Kim HK. Intravitreal bevacizumab to treat acute central serous chorioretinopathy: short-term effect. Ophthalmologica 2009; 223(5): 343-347.
2. Torres-Soriano ME, Garcia-Aguirre G, Kon-Jara V, Ustariz-Gonzales O, Abraham-Marin M, Ober MD et al. A pilot study of intravitreal bevacizumab for the treatment of central serous chorioretinopathy (case reports). Graefes Arch Clin Exp Ophthalmol 2008; 246(9): 1235-1239.
3. Li XJ, Zhang JS. Intravitreal bevacizumab injection for chronic central serous chorioretinopathy. Chin Med J (Engl) 2010; 123(15): 2145-2147.
4. Yannuzzi LA. Type-A behavior and central serous chorioretinopathy. Retina 1987; 7(2): 111-131.
5. Lafaut BA, Salati C, Priem H, De Laey JJ. Indocyanine green angiography is of value for the diagnosis of chronic central serous chorioretinopathy in elderly patients. Graefes Arch Clin Exp Ophthalmol 1998; 236(7): 513-521.
6. Prunte C. Indocyanine green angiographic findings in central serous chorioretinopathy. Int Ophthalmol 1995; 19(2): 77-82.
7. Guyer DR, Yannuzzi LA, Slakter JS, Sorenson JA, Ho A, Orlock D. Digital indocyanine green videoangiography of central serous chorioretinopathy. Arch Ophthalmol 1994; 112(8): 1057-1062.
8. Prunte C, Flammer J. Choroidal capillary and venous congestion in central serous chorioretinopathy. Am J Ophthalmol 1996; 121(1): 26-34.
9. Gemenetzi M, De Salvo G, Lotery AJ. Central serous chorioretinopathy: an update on pathogenesis and treatment. Eye (Lond) 2010; 24(12): 1743-1756.
10. Shukla D, Kolluru C, Vignesh TP, Karthikprakash S, Kim R. Transpupillary thermotherapy for subfoveal leaks in central serous chorioretinopathy. Eye (Lond) 2008; 22(1): 100-106.
11. Iida T, Yannuzzi LA, Spaide RF, Borodoker N, Carvalho CA, Negrao S. Cystoid macular degeneration in chronic central serous chorioretinopathy. Retina 2003; 23(1): 1-7; quiz 137-138.
12. Piccolino FC, de la Longrais RR, Ravera G, Eandi CM, Ventre L, Abdollahi A et al. The foveal photoreceptor layer and visual acuity loss in central serous chorioretinopathy. Am J Ophthalmol 2005; 139(1): 87-99.
13. Lim SJ, Roh MI, Kwon OW. Intravitreal bevacizumab injection for central serous chorioretinopathy. Retina 2010; 30(1): 100-106.
14. Burumcek E, Mudun A, Karacorlu S, Arslan MO. Laser photocoagulation for persistent central serous retinopathy: results of long-term follow-up. Ophthalmology 1997; 104(4): 616-622.
15. Wang M, Sander B, la Cour M, Larsen M. Clinical characteristics of subretinal deposits in central serous chorioretinopathy. Acta Ophthalmol Scand 2005; 83(6): 691-696.
16. Ross A, Ross AH, Mohamed Q. Review and update of central serous chorioretinopathy. Curr Opin Ophthalmol 2011; 22(3): 166-173.
17. Wang M, Munch IC, Hasler PW, Prunte C, Larsen M. Central serous chorioretinopathy. Acta Ophthalmol 2008; 86(2): 126-145.
18. Cardillo Piccolino F, Eandi CM, Ventre L, Rigault de la Longrais RC, Grignolo FM. Photodynamic therapy for chronic central serous chorioretinopathy. Retina 2003; 23(6): 752-763.
19. Chan WM, Lam DS, Lai TY, Tam BS, Liu DT, Chan CK. Choroidal vascular remodelling in central serous chorioretinopathy after indocyanine green guided photodynamic therapy with verteporfin: a novel treatment at the primary disease level. Br J Ophthalmol 2003; 87(12): 1453-1458.
20. Inoue R, Sawa M, Tsujikawa M, Gomi F. Association between the efficacy of photodynamic therapy and indocyanine green angiography findings for central serous chorioretinopathy. Am J Ophthalmol 2010; 149(3): 441-446. e441-e442.
21. Wu L, Martinez-Castellanos MA, Quiroz-Mercado H, Arevalo JF, Berrocal MH, Farah ME et al. Twelve-month safety of intravitreal injections of bevacizumab (Avastin): results of the Pan-American Collaborative Retina Study Group (PACORES). Graefes Arch Clin Exp Ophthalmol 2008; 246(1): 81-87.
22. Lim JW, Kim MU. The efficacy of intravitreal bevacizumab for idiopathic central serous chorioretinopathy. Graefes Arch Clin Exp Ophthalmol 2011; 249(7): 969-974.
23. Schaal KB, Hoeh AE, Scheuerle A, Schuett F, Dithmar S. Intravitreal bevacizumab for treatment of chronic central serous chorioretinopathy. Eur J Ophthalmol 2009; 19(4): 613-617.
24. Inoue M, Kadonosono K, Watanabe Y, Kobayashi S, Yamane S, Arakawa A. Results of one-year follow-up examinations after intravitreal bevacizumab administration for chronic central serous chorioretinopathy. Ophthalmologica 2011; 225(1): 37-40.
25. Lee ST, Adelman RA. The treatment of recurrent central serous chorioretinopathy with intravitreal bevacizumab. J Ocul Pharmacol Ther 2011; 27(6): 611-614.
26. Verhagen AP, de Vet HC, de Bie RA, Kessels AG, Boers M, Bouter LM et al. The Delphi list: a criteria list for quality assessment of randomized clinical trials for conducting systematic reviews developed by Delphi consensus. J Clin Epidemiol 1998; 51(12): 1235-1241.
27. Review Manager (RevMan) [Computer program]. Version 5.1. The Nordic Cochrane Centre, The Cochrane Collaboration: Copenhagen, 2011.
28. Lee JY, Chae JB, Yang SJ, Kim JG, Yoon YH. Intravitreal bevacizumab versus the conventional protocol of photodynamic therapy for treatment of chronic central serous chorioretinopathy. Acta Ophthalmol 2011; 89(3): e293-e294.
29. Semeraro F, Romano MR, Danzi P, Morescalchi F, Costagliola C. Intravitreal bevacizumab versus low-fluence photodynamic therapy for treatment of chronic central serous chorioretinopathy. Jpn J Ophthalmol 2012; 56(6): 608-612.
30. Lim JW, Ryu SJ, Shin MC. The effect of intravitreal bevacizumab in patients with acute central serous chorioretinopathy. Korean J Ophthalmol 2010; 24(3): 155-158.
31. Aydin E. The efficacy of intravitreal bevacizumab for acute central serous chorioretinopathy. J Ocul Pharmacol Ther 2013; 29(1): 10-13.
32. Artunay O, Yuzbasioglu E, Rasier R, Sengul A, Bahcecioglu H. Intravitreal bevacizumab in treatment of idiopathic persistent central serous chorioretinopathy: a prospective, controlled clinical study. Curr Eye Res 2010; 35(2): 91-98.
33. Koss MJ, Beger I, Koch FH. Subthreshold diode laser micropulse photocoagulation versus intravitreal injections of bevacizumab in the treatment of central serous chorioretinopathy. Eye (Lond) 2012; 26(2): 307-314.
34. Hussain D, Gass JD. Idiopathic central serous chorioretinopathy. Indian J Ophthalmol 1998; 46(3): 131-137.
35. Pikkel J, Beiran I, Ophir A, Miller B. Acetazolamide for central serous retinopathy. Ophthalmology 2002; 109(9): 1723-1725.
36. Nielsen JS, Weinreb RN, Yannuzzi L, Jampol LM. Mifepristone treatment of chronic central serous chorioretinopathy. Retina 2007; 27(1): 119-122.
37. Caccavale A, Romanazzi F, Imparato M, Negri A, Morano A, Ferentini F. Low-dose aspirin as treatment for central serous chorioretinopathy. Clin Ophthalmol 2010; 4: 899-903.
38. Tatham A, Macfarlane A. The use of propranolol to treat central serous chorioretinopathy: an evaluation by serial OCT. J Ocul Pharmacol Ther 2006; 22(2): 145-149.
39. Forooghian F, Meleth AD, Cukras C, Chew EY, Wong WT, Meyerle CB. Finasteride for chronic central serous chorioretinopathy. Retina 2011; 31(4): 766-771.
40. Yannuzzi LA, Slakter JS, Gross NE, Spaide RF, Costa D, Huang SJ et al. Indocyanine green angiography-guided photodynamic therapy for treatment of chronic central serous chorioretinopathy: a pilot study. Retina 2003; 23(3): 288-298.
41. Mehany SA, Shawkat AM, Sayed MF, Mourad KM. Role of Avastin in management of central serous chorioretinopathy. Saudi J Ophthalmol 2010; 24(3): 69-75.
42. Jamil AZ, Rahman FU, Iqbal K, Ansari HM, Iqbal W, Mirza KA. Intravitreal bevacizumab in central serous chorioretinopathy. J Coll Physicians Surg Pak 2012; 22(6): 363-366.
43. Entezari M, Ramezani A, Yaseri M. Intravitreal bevacizumab for treatment of refractory central serous choroidoretinopathy. Korean J Ophthalmol 2012; 26(2): 139-142.
44. Heiduschka P, Fietz H, Hofmeister S, Schultheiss S, Mack AF, Peters S et al. Penetration of bevacizumab through the retina after intravitreal injection in the monkey. Invest Ophthalmol Vis Sci 2007; 48(6): 2814-2823.
45. Scott IU, Edwards AR, Beck RW, Bressler NM, Chan CK, Elman MJ et al. A phase II randomized clinical trial of intravitreal bevacizumab for diabetic macular edema. Ophthalmology 2007; 114(10): 1860-1867.
46. Soheilian M, Ramezani A, Obudi A, Bijanzadeh B, Salehipour M, Yaseri M et al. Randomized trial of intravitreal bevacizumab alone or combined with triamcinolone versus macular photocoagulation in diabetic macular edema. Ophthalmology 2009; 116(6): 1142-1150.
47. Haritoglou C, Kook D, Neubauer A, Wolf A, Priglinger S, Strauss R et al. Intravitreal bevacizumab (Avastin) therapy for persistent diffuse diabetic macular edema. Retina 2006; 26(9): 999-1005.
48. Fang X, Sakaguchi H, Gomi F, Oshima Y, SawaM, TsujikawaM et al. Efficacy and safety of one intravitreal injection of bevacizumab in diabetic macular oedema. Acta Ophthalmol 2008; 86(7): 800-805.
49. Sharma S, Johnson D, AbouammohM, Hollands S, Brissette A. Rate of serious adverse effects in a series of bevacizumab and ranibizumab injections. Can J Ophthalmol 2012; 47(3): 275-279.
50. Lim JW, Kim MU, Shin MC. Aqueous humor and plasma levels of vascular endothelial growth factor and interleukin-8. in patients with central serous chorioretinopathy. Retina 2010; 30(9): 1465-1471.